Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Total Debt: 2009-2024

Historic Total Debt for Cross Country Healthcare (CCRN) over the last 16 years, with Q4 2024 value amounting to $4.4 million.

  • Cross Country Healthcare's Total Debt fell 3507.51% to $4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.4 million, marking a year-over-year decrease of 3507.51%. This contributed to the annual value of $4.4 million for FY2024, which is 3507.51% down from last year.
  • As of Q4 2024, Cross Country Healthcare's Total Debt stood at $4.4 million, which was down 3507.51% from $4.1 million recorded in Q3 2024.
  • Over the past 5 years, Cross Country Healthcare's Total Debt peaked at $231.9 million during Q1 2022, and registered a low of $4.1 million during Q1 2024.
  • Its 5-year average for Total Debt is $85.9 million, with a median of $63.0 million in 2020.
  • As far as peak fluctuations go, Cross Country Healthcare's Total Debt surged by 22486.31% in 2021, and later plummeted by 9728.37% in 2024.
  • Cross Country Healthcare's Total Debt (Quarter) stood at $58.3 million in 2020, then skyrocketed by 224.86% to $189.3 million in 2021, then dropped by 17.45% to $156.2 million in 2022, then plummeted by 95.65% to $6.8 million in 2023, then crashed by 35.08% to $4.4 million in 2024.
  • Its Total Debt was $4.4 million in Q4 2024, compared to $4.1 million in Q3 2024 and $4.1 million in Q2 2024.